Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs SELLAS Life Sciences Group, Inc. (SLS)

NewAmsterdam Pharma Company N.V. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and SELLAS Life Sciences Group, Inc. are of similar size ($2.5B and $2.3B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −3,644.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, SELLAS Life Sciences Group, Inc. leads on 10 and NewAmsterdam Pharma Company N.V. on 4.

Valuation

Metric NAMS SLS Biotechnology median
P/E n/m n/m 8.50
P/S 343.55 179.81 9.71
P/B 3.87 13.72 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 254.35 166.67 9.21
Earnings yield (10.89%) (2.10%) (33.15%)
Free cash flow yield (5.87%) (2.04%) (25.50%)

Profitability

Metric NAMS SLS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (3,432.20%) 0.00% 0.00%
Net margin (3,644.21%) 0.00% 0.00%
Free cash flow margin (2,018.28%) 0.00% 0.00%
Return on equity (36.81%) (39.63%) (56.36%)
Return on assets (34.16%) (36.54%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NAMS SLS Biotechnology median
Revenue growth (TTM) (88.87%) — 6.02%
EPS growth (last fiscal year) 32.81% 50.00% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.03 18.83 4.72
Net debt to EBITDA 2.83 2.54 0.96

Dividend

Metric NAMS SLS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NAMS SLS Biotechnology median
Market cap 2.46b 2.29b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack